Rocket Lab received an $816 million U.S. Space Force contract in December, boosting stock prices. Morgan Stanley upgraded the stock to “Overweight” with a $105 target, while Bank of America set a $120 target. However, NASA’s cancellation of a $4 billion Mars program and Neutron rocket testing failure highlighted execution risks. Rocket Lab’s stock climbed 14.8% in January, with successful rocket launches. Despite setbacks, the company remains a key player in the space industry. Investors should weigh risks before buying Rocket Lab stock, but the company’s growth potential remains strong.

Read more at Nasdaq: Why Rocket Lab Stock Skyrocketed To Start 2026